SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

SION

Sionna Therapeutics, Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The stock will trade on Phase 2a and Phase 1 topline data catalysts this summer, not on Q1 financials. Watch for sweat chloride data from PreciSION CF, a clinically meaningful reduction would validate SION-719's mechanism and likely drive a re-rating. The 88% analyst buy rating and $2.1B market cap already price in some optimism; a data miss would be severely punished given the binary nature of the readout.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$40.94
T+0 close · May 12, 2026 · via day close
Latest settled
+21.18%
T+60 · $49.61
Vs SPY
+16.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $40.94entry
  2. T+1 · 6mo ago +5.32%α +4.75% · $43.12
  3. T+5 · 6mo ago −4.15%α −4.23% · $39.24
  4. T+20 · 5mo ago −16.88%α −15.15% · $34.03
  5. T+60 · 3mo ago +21.18%α +16.79% · $49.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sionna reported Q1 2026 GAAP EPS of -$0.60, a 3.2% beat vs consensus of -$0.62, but net loss widened to $26.8M from $16.5M a year ago on higher R&D and G&A spending. The key catalyst is the on-track summer 2026 topline data from the Phase 2a PreciSION CF trial and Phase 1 dual-combination trial, which will determine whether SION-719 can expand CF treatment options. Cash of $289.9M funds operations into 2028, removing near-term dilution risk.

Key Financial Metrics

EPS
−$0.60
est −$0.62 · +3.2%
Rating
in line

Key Facts

  • Q1 2026 GAAP EPS -$0.60 vs consensus -$0.62 (3.2% beat)
  • Net loss widened to $26.8M from $16.5M YoY on higher R&D ($19.0M vs $13.7M) and G&A ($10.6M vs $6.0M)
  • Phase 2a PreciSION CF trial of SION-719 enrollment completed; topline data expected summer 2026
  • Phase 1 dual-combination trial of SION-451 with SION-2222 and SION-109 on track for summer 2026 topline data
  • Cash, cash equivalents and marketable securities $289.9M; expected to fund operations into 2028
  • No revenue reported (pre-commercial biotech)

Financial Impact

Net loss of $26.8M in Q1 2026 vs $16.5M in Q1 2025; cash burn rate ~$10M/month

net losscash positionR&D spend

Risk Factors

  • Phase 2a topline data could fail to show clinically meaningful sweat chloride reduction, undermining the NBD1 stabilizer thesis
  • Cash burn rate increased 62% YoY; if data disappoints, financing risk emerges despite current runway into 2028
  • Insider selling of $31.7M in last 30 days may signal lack of confidence ahead of data readout

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292667

Track record

22 reports on SION

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
  2. Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
  5. Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
  6. Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
  7. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
  8. Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
  9. Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
  10. Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (9h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026